Search

Your search keyword '"Matzkies, Franziska"' showing total 8 results
Start Over Author "Matzkies, Franziska" Journal rheumatology
8 results on '"Matzkies, Franziska"'

1. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study

Author

Price, Elizabeth, primary, Bombardieri, Michele, additional, Kivitz, Alan, additional, Matzkies, Franziska, additional, Gurtovaya, Oksana , additional, Pechonkina, Alena, additional, Jiang, Wendy, additional, Downie, Bryan, additional, Mathur, Anubhav, additional, Mozaffarian, Afsaneh, additional, Mozaffarian, Neelufar, additional, and Gottenberg, J Eric, additional

Published
2022
Full Text
View/download PDF

2. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study

Author

Werth, Victoria P, primary, Fleischmann, Roy, additional, Robern, Michael, additional, Touma, Zahi, additional, Tiamiyu, Iyabode, additional, Gurtovaya, Oksana, additional, Pechonkina, Alena, additional, Mozaffarian, Afsaneh, additional, Downie, Bryan, additional, Matzkies, Franziska, additional, and Wallace, Daniel, additional

Published
2021
Full Text
View/download PDF

3. P133 Filgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data

Author

Walker, David, primary, Kivitz, Alan, additional, Tanaka, Yoshiya, additional, Lee, Susan, additional, Ye, Lei, additional, Hu, Hao, additional, Matzkies, Franziska, additional, Bartok, Beatrix, additional, Guo, Ying, additional, Sundy, John S, additional, Jahreis, Angelika, additional, Besuyen, Robin, additional, Combe, Bernard, additional, van der Heijde, Désirée, additional, Simon-Campos, J-Abraham, additional, Baraf, Herbert S B, additional, Kumar, Uma, additional, Tasset, Chantal, additional, Mozaffarian, Neelufar, additional, Landewé, Robert B M, additional, Bae, Sang-Cheol, additional, Keystone, Edward, additional, and Nash, Peter, additional

Published
2021
Full Text
View/download PDF

4. P217 Efficacy and safety of filgotinib for patients with RA naïve to MTX therapy: FINCH3 primary outcome results

Author

McKay, Neil, primary, van der Heijde, Désirée, primary, Westhovens, Rene, primary, Rigby, William F. C, primary, Ching, Daniel W. T, primary, Bartok, Beatrix, primary, Matzkies, Franziska, primary, Yin, Zhaoyu, primary, Guo, Ying, primary, Tasset, Chantal, primary, Sundy, John S, primary, Mozaffarian, Neelufar, primary, Messina, Osvaldo D, primary, Landewé, Robert B. M, primary, Atsumi, Tatsuya, primary, and Burmester, Gerd R, primary

Published
2020
Full Text
View/download PDF

5. P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results

Author

Walker, David, primary, Combe, Bernard G, primary, Kivitiz, Alan J, primary, Tanaka, Yoshiya, primary, van der Heijde, Désirée, primary, Matzkies, Franziska, primary, Bartok, Beatrix, primary, Ye, Lie, primary, Guo, Ying, primary, Tasset, Chantal, primary, Sundy, John S, primary, Mozaffarian, Neelufar, primary, Landewé, Robert B. M, primary, Bae, Sang-Cheol, primary, Keystone, Edward C, primary, and Nash, Peter, primary

Published
2020
Full Text
View/download PDF

6. O09 Pooled safety analyses from Phase 3 studies of filgotinib in patients with RA

Author

Walker, David, primary, Winthrop, Kevin, primary, Genovese, Mark C, primary, Combe, Bernard G, primary, Tanaka, Yoshiya, primary, Kivitiz, Alan, primary, Matzkies, Franziska, primary, Bartok, Beatrix, primary, Ye, Lie, primary, Guo, Ying, primary, Tasset, Chantal, primary, Sundy, John S, primary, Keystone, Edward, primary, Westhovens, Rene, primary, Rigby, William, primary, and Burmester, Gerd R, primary

Published
2020
Full Text
View/download PDF

7. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.

Author

Werth, Victoria P, Fleischmann, Roy, Robern, Michael, Touma, Zahi, Tiamiyu, Iyabode, Gurtovaya, Oksana, Pechonkina, Alena, Mozaffarian, Afsaneh, Downie, Bryan, Matzkies, Franziska, and Wallace, Daniel

Subjects
THERAPEUTIC use of antineoplastic agents, DRUG efficacy, RESEARCH, LUPUS erythematosus, JANUS kinases, PROTEIN-tyrosine kinase inhibitors, RANDOMIZED controlled trials, SEVERITY of illness index, BLIND experiment, DESCRIPTIVE statistics, NEUROTRANSMITTER uptake inhibitors, STATISTICAL sampling
Abstract

Objectives To explore the safety and efficacy of filgotinib (FIL), a Janus kinase 1 inhibitor, and lanraplenib (LANRA), a spleen kinase inhibitor, in cutaneous lupus erythematosus (CLE). Methods This was a phase 2, randomized, double-blind, placebo-controlled, exploratory, proof-of-concept study of LANRA (30 mg), FIL (200 mg) or placebo (PBO) once daily for 12 weeks in patients with active CLE. At week 12, PBO patients were rerandomized 1:1 to receive LANRA or FIL for up to 36 additional weeks. Results Of 47 randomized patients, 45 were treated (PBO, n  = 9; LANRA, n  = 19; FIL, n  = 17). The primary endpoint [change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at week 12] was not met. The least squares mean CLASI-A score change from baseline was −5.5 (s. e. 2.56) with PBO, −4.5 (1.91) with LANRA and −8.7 (1.85) with FIL. Numerical differences between FIL and PBO were greater in select subgroups. A ≥5-point improvement in the CLASI-A score at week 12 was achieved by 50.0%, 56.3% and 68.8% in the PBO, LANRA and FIL arms, respectively. A numerically greater proportion of patients in the FIL arm (50%) also achieved ≥50% improvement in the CLASI-A score at week 12 (37.5% PBO, 31.3% LANRA). Most adverse events (AEs) were mild or moderate in severity. Two serious AEs were reported with LANRA and one with FIL. Conclusion The primary endpoint was not met. Select subgroups displayed a numerically greater treatment response to FIL relative to PBO. LANRA and FIL were generally well tolerated. Trial registration ClinicalTrials.gov identifier NCT03134222 [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

8. 086 Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs

Author

Walker, David, primary, Genovese, Mark C, additional, Kalunian, Kenneth, additional, Gottenberg, Jacques-Eric, additional, de Vlam, Kurt, additional, Mozaffarian, Neelufar, additional, Bartok, Beatrix, additional, Matzkies, Franziska, additional, Gao, Jie, additional, Guo, Ying, additional, Tasset, Chantal, additional, Sundy, John S, additional, and Takeuchi, Tsutomu, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results